
### [NCIT:C40392](http://purl.obolibrary.org/obo/NCIT_C40392)
**Label:** Myoepithelial Tumor

**Subclasses:** [NCIT:C5978](http://purl.obolibrary.org/obo/NCIT_C5978) (Benign Salivary Gland Myoepithelioma), [NCIT:C6899](http://purl.obolibrary.org/obo/NCIT_C6899) (Breast Adenomyoepithelioma), [NCIT:C5143](http://purl.obolibrary.org/obo/NCIT_C5143) (Malignant Breast Adenomyoepithelioma), [NCIT:C5144](http://purl.obolibrary.org/obo/NCIT_C5144) (Benign Breast Adenomyoepithelioma), [NCIT:C7596](http://purl.obolibrary.org/obo/NCIT_C7596) (Malignant Myoepithelioma), [NCIT:C7442](http://purl.obolibrary.org/obo/NCIT_C7442) (Benign Myoepithelioma), [NCIT:C6581](http://purl.obolibrary.org/obo/NCIT_C6581) (Parachordoma), [NCIT:C40388](http://purl.obolibrary.org/obo/NCIT_C40388) (Periductal Breast Myoepitheliosis), [NCIT:C40389](http://purl.obolibrary.org/obo/NCIT_C40389) (Breast Myoepithelial Tumor), [NCIT:C121787](http://purl.obolibrary.org/obo/NCIT_C121787) (Malignant Mixed Tumor, Not Otherwise Specified), [NCIT:C40395](http://purl.obolibrary.org/obo/NCIT_C40395) (Malignant Breast Myoepithelioma), [NCIT:C121786](http://purl.obolibrary.org/obo/NCIT_C121786) (Mixed Tumor, Not Otherwise Specified), [NCIT:C40385](http://purl.obolibrary.org/obo/NCIT_C40385) (Breast Myoepitheliosis), [NCIT:C40393](http://purl.obolibrary.org/obo/NCIT_C40393) (Salivary Gland Myoepithelial Tumor), [NCIT:C35700](http://purl.obolibrary.org/obo/NCIT_C35700) (Salivary Gland Myoepithelial Carcinoma), 

**Class expressions from DL-Learner:**

- Thing 51.79%
- [CL:0000185](http://purl.obolibrary.org/obo/CL_0000185) (myoepithelial cell) 45.36%
- [CL:0000185](http://purl.obolibrary.org/obo/CL_0000185) (myoepithelial cell) and (not ([NCIT:C39114](http://purl.obolibrary.org/obo/NCIT_C39114) (IGF-1 Signaling Pathway))) 45.36%
- [CL:0000185](http://purl.obolibrary.org/obo/CL_0000185) (myoepithelial cell) and (not ([NCIT:C39112](http://purl.obolibrary.org/obo/NCIT_C39112) (IFN Gamma Signaling Pathway))) 45.36%
- [CL:0000185](http://purl.obolibrary.org/obo/CL_0000185) (myoepithelial cell) and (not ([NCIT:C39103](http://purl.obolibrary.org/obo/NCIT_C39103) (ERBB2 Signaling Pathway))) 45.36%
- [CL:0000185](http://purl.obolibrary.org/obo/CL_0000185) (myoepithelial cell) and (not ([NCIT:C39102](http://purl.obolibrary.org/obo/NCIT_C39102) (Skeletal Myogenesis Pathway))) 45.36%
- [CL:0000185](http://purl.obolibrary.org/obo/CL_0000185) (myoepithelial cell) and (not ([NCIT:C39101](http://purl.obolibrary.org/obo/NCIT_C39101) (Human Cytomegalovirus Infection Pathway))) 45.36%
- [CL:0000185](http://purl.obolibrary.org/obo/CL_0000185) (myoepithelial cell) and (not ([NCIT:C39094](http://purl.obolibrary.org/obo/NCIT_C39094) (Inhibition of Cellular Proliferation by Gleevec Pathway))) 45.36%
- [CL:0000185](http://purl.obolibrary.org/obo/CL_0000185) (myoepithelial cell) and (not ([NCIT:C39092](http://purl.obolibrary.org/obo/NCIT_C39092) (Growth Hormone Signaling Pathway))) 45.36%
- [CL:0000185](http://purl.obolibrary.org/obo/CL_0000185) (myoepithelial cell) and (not ([NCIT:C39091](http://purl.obolibrary.org/obo/NCIT_C39091) (Corticosteroid Cardioprotection Pathway))) 45.36%
- [CL:0000185](http://purl.obolibrary.org/obo/CL_0000185) (myoepithelial cell) and (not ([NCIT:C39088](http://purl.obolibrary.org/obo/NCIT_C39088) (G2/M Checkpoint Pathway))) 45.36%
- [CL:0000185](http://purl.obolibrary.org/obo/CL_0000185) (myoepithelial cell) and (not ([NCIT:C39079](http://purl.obolibrary.org/obo/NCIT_C39079) (Fc Epsilon Receptor I Signaling Pathway BioCarta))) 45.36%
- [CL:0000185](http://purl.obolibrary.org/obo/CL_0000185) (myoepithelial cell) and (not ([NCIT:C39072](http://purl.obolibrary.org/obo/NCIT_C39072) (Erk1/Erk2 MAPK Signaling Pathway))) 45.36%
- [CL:0000185](http://purl.obolibrary.org/obo/CL_0000185) (myoepithelial cell) and (not ([NCIT:C39071](http://purl.obolibrary.org/obo/NCIT_C39071) (Neuronal Survival Pathway))) 45.36%
- [CL:0000185](http://purl.obolibrary.org/obo/CL_0000185) (myoepithelial cell) and (not ([NCIT:C39069](http://purl.obolibrary.org/obo/NCIT_C39069) (ErbB3 Receptor Recycling Pathway))) 45.36%


